Selected data models

You must log in to select data models for download or further analysis.

6 Search results.
Relevance Rating New first Old first

GSK Biologicals' oral live attenuated human rotavirus vaccine (RIX4414) as primary dosing of healthy infants; NCT00289172 - Non-Serious Adverse Events

- 4/25/19 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Administrative documentation, Non-serious Adverse Event
Study ID: 103792 Clinical Study ID: 103792 Study Title: A multicenter study of the immunogenicity & safety of 2 doses of GSK Biologicals’ oral live attenuated human rotavirus vaccine (RIX4414) as primary dosing of healthy infants in India aged approximately 8 wks at the time of the first dose Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00289172 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: Rotavirus Vaccine Trade Name: BIO ROTA; Rotarix Study Indication: Infections, Rotavirus

Efficacy, Safety and Immunogenicity of Oral HRV Vaccine NCT00241644 - Non-serious AE

- 11/19/18 - 1 form, 3 itemgroups, 10 items, 1 language
Itemgroups: Administrative Data, Non-serious Adverse Events, Non-serious Adverse Events Leading to Drop Out
Study ID: 102248 Clinical Study ID: 102248 Study Title: Multi-Center Study to Assess the Efficacy, Safety and Immunogenicity of 2 or 3 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine Given Concomitantly With Routine EPI Vaccinations in Healthy Infants Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00241644 Study Link: https://clinicaltrials.gov/ct2/show/NCT00241644 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: Rotavirus Vaccine Trade Name: Rotarix Study Indication: Infections, Rotavirus The visits are defined as follows: Visit 1: (Study/Participation) Day 0, Age: 5-10 weeks, Dose 1 Visit 2: (Study/Participation) Month 1, 30-48 days after Visit 1, Dose 2 Visit 3: (Study/Participation) Month 2, 30-48 days after Visit 2, Dose 3 Visit 4: (Study/Participation) Month 3, 30-48 days after Visit 3, Visit 5: (Study/Participation) 1 year of age, 343-391 days of age For amendment 5: Visit 5: (Study/Participation) 21-48 days after Visit 4 Visit 6: (Study/Participation) 1 year of age, 343-391 days of age This form contains information about non-serious adverse events, occuring during the study. It should be filled in in case of drop-out due to non-serious AE.

GSK Biologicals' oral HRV vaccine given with OPV in infants NCT00139334 - Non-Serious Adverse Events

- 10/17/18 - 1 form, 3 itemgroups, 11 items, 1 language
Itemgroups: administrative data, Non-Serious adverse Events, Characteristics of non-serious adverse events
Study ID: 103992 Clinical Study ID: 103992 Study Title: Evaluate immunogenicity, reactogenicity & safety of 2 doses of GSK Biologicals’ oral live attenuated HRV vaccine (RIX4414 at 106.5 CCID50) when given concomitantly with OPV versus given alone (HRV vaccine dose given 15 days after the OPV dose) in healthy infants in Bangladesh Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00139334 https://clinicaltrials.gov/ct2/show/NCT00139334 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Rotavirus Vaccine Trade Name: Rotarix Study Indication: Haemophilus influenzae type b; Neisseria Meningitidis This form is for documentation of non-serious adverse events occuring during the study, excluding solicited adverse events (to be documented in the "unsolicited and solicited adverse events" form at visits 3 and 5).

GSK Biologicals' oral HRV vaccine given with OPV in infants NCT00139334 - Unsolicited and Solicited Adverse Events post Study Vaccination

- 10/17/18 - 1 form, 4 itemgroups, 33 items, 1 language
Itemgroups: Administrative Data, Unsolicited Adverse Events, Solicited Adverse Events - General Symptoms, Intensity of Symptoms
Study ID: 103992 Clinical Study ID: 103992 Study Title: Evaluate immunogenicity, reactogenicity & safety of 2 doses of GSK Biologicals’ oral live attenuated HRV vaccine (RIX4414 at 106.5 CCID50) when given concomitantly with OPV versus given alone (HRV vaccine dose given 15 days after the OPV dose) in healthy infants in Bangladesh Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00139334 https://clinicaltrials.gov/ct2/show/NCT00139334 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Rotavirus Vaccine Trade Name: Rotarix Study Indication: Haemophilus influenzae type b; Neisseria Meningitidis This form is for documentation of unsolicited and solicited adverse events at Visit 3 (Dose 1 of Study Vaccination) and Visit 5 (Dose 2 of Study Vaccination) Visit 3 -> Timing: Day 45, Age: 12 weeks +/- 1 week. Visit 5 -> Timing: Day 75, Age: 16 weeks +/- 1 week.

Rotavirus Vaccine RIX4414 Study NCT00289172 - Serious Adverse Event

- 4/13/18 - 1 form, 14 itemgroups, 51 items, 1 language
Itemgroups: Header, Serious adverse event, Seriousness, Demography data, SECTION 4, SECTION 5, Relevant Medical Conditions, Other relevant risk factors, Document section Concomitant Medications, Details of investigational product, Details of relevant Assessments, Narrative Remarks, Investigator's signature, follow-up information SAE
A multicenter study of the immunogenicity & safety of 2 doses of GSK Biologicals’oral live attenuated human rotavirus vaccine (RIX4414) as primary dosing of healthy infants in India aged approximately 8 wks at the time of the first dose Study ID:103792 Clinical Study ID:103792 Study Title: A multicenter study of the immunogenicity & safety of 2 doses of GSK Biologicals’oral live attenuated human rotavirus vaccine (RIX4414) as primary dosing of healthy infants in India aged approximately 8 wks at the time of the first dose Patient Level Data:Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier:NCT00289172 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: Rotavirus Vaccine Trade Name: BIO ROTA; Rotarix Study Indication: Infections, Rotavirus CRF Seiten: 375-430

Rotavirus Vaccine RIX4414 Study NCT00289172 - gastroenteritis, concomitant vaccination, medication and non-serious adverse events

- 4/13/18 - 1 form, 8 itemgroups, 38 items, 2 languages
Itemgroups: Header, Gastroenteritis Episodes, Gastroenteritis protocol, Concomitant Vaccination, Concomitant Vaccination, Medication, Medication, Non-serious Adverse Events
A multicenter study of the immunogenicity & safety of 2 doses of GSK Biologicals’oral live attenuated human rotavirus vaccine (RIX4414) as primary dosing of healthy infants in India aged approximately 8 wks at the time of the first dose Study ID:103792 Clinical Study ID:103792 Study Title: A multicenter study of the immunogenicity & safety of 2 doses of GSK Biologicals’oral live attenuated human rotavirus vaccine (RIX4414) as primary dosing of healthy infants in India aged approximately 8 wks at the time of the first dose Patient Level Data:Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier:NCT00289172 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: Rotavirus Vaccine Trade Name: BIO ROTA; Rotarix Study Indication: Infections, Rotavirus CRF Seiten: 375-430

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial